These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21254154)

  • 1. Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.
    Sugimoto M; Oka M; Tsunemori H; Yamashita M; Kakehi Y
    Prostate; 2011 Mar; 71(4):438-44. PubMed ID: 21254154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.
    Oka M; Ueda M; Oyama T; Kyotani J; Tanaka M
    Prostate; 2009 Sep; 69(13):1404-10. PubMed ID: 19489033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.
    Shibuya S; Xia Z; Sugimoto M; Ueda N; Haba R; Kakehi Y
    Urology; 2014 Mar; 83(3):528-34. PubMed ID: 24581515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis.
    Tsunemori H; Sugimoto M; Xia Z; Taoka R; Oka M; Kakehi Y
    Urology; 2011 Jun; 77(6):1507.e15-20. PubMed ID: 21624608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis.
    Tagaya M; Oka M; Ueda M; Takagaki K; Tanaka M; Ohgi T; Yano J
    Cytokine; 2009 Sep; 47(3):185-93. PubMed ID: 19616448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia.
    Matsumoto S; Hanai T; Matsui T; Oka M; Tanaka M; Uemura H
    Phytother Res; 2010 Feb; 24(2):301-3. PubMed ID: 19585469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction.
    Oka M; Fukui T; Ueda M; Tagaya M; Oyama T; Tanaka M
    J Urol; 2009 Jul; 182(1):382-90. PubMed ID: 19447421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
    Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
    Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying.
    Kawai Y; Oka M; Kyotani J; Oyama T; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Sep; 32(7):1031-7. PubMed ID: 23143863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of eviprostat on bladder overactivity in an experimental cystitis rat model.
    Kobayashi M; Nomura M; Nishii H; Matsumoto S; Fujimoto N; Matsumoto T
    Int J Urol; 2008 Apr; 15(4):356-60. PubMed ID: 18380828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement by phytotherapeutic agent of detrusor overactivity, down-regulation of pharmacological receptors and urinary cytokines in rats with cyclophosphamide induced cystitis.
    Nasrin S; Masuda E; Kugaya H; Ito Y; Yamada S
    J Urol; 2013 Mar; 189(3):1123-9. PubMed ID: 23000860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia.
    Matsui T; Oka M; Fukui T; Tanaka M; Oyama T; Sagawa K; Nomiya M; Yamaguchi O
    Int J Urol; 2012 Jul; 19(7):669-75. PubMed ID: 22458726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 15. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T; Wakabayashi A; Kaneko S; Kurita T
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
    Ishigooka M; Hashimoto T; Hayami S; Tomaru M; Nakada T; Mitobe K
    Int Urol Nephrol; 1995; 27(1):61-6. PubMed ID: 7542229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms by which a phytotherapeutic drug influences bladder activity in rats.
    Sugaya K; Nishijima S; Tasaki S; Kadekawa K; Miyazato M; Ogawa Y
    J Urol; 2008 Feb; 179(2):770-4. PubMed ID: 18082195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment to suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia.
    Yamada S
    Int J Urol; 2012 Jul; 19(7):675; author reply 675. PubMed ID: 22725604
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of prostamol-Uno on oxidative and local immune status in patients with benign prostatic hyperplasia and chronic prostatitis].
    Seregin SP; Bratchikov OI; Konoplia AI; Shestakov SG; Dolzhenkov SD; Novikov AV; Shatokhin MN; Kotov AV
    Urologiia; 2002; (4):14-6. PubMed ID: 12357892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.